HANSHOW
27.3.2024 10:56:30 CET | Business Wire | Press release
From March 13th to 15th, the 24th China Retail Expo was held at Shanghai's National Convention and Exhibition Center. Under the theme "Green Digitalization and GenAI for Sustainable Retail," Hanshow debuted its pioneering GenAI product strategy, marking a significant leap forward in retail's AI era. The showcase included the upgraded Hanshow Polaris Pro series electronic shelf labels (ESL) and a new green digital store solution, reaffirming Hanshow's dedication to providing retailers with cutting-edge technologies for enhanced efficiency, improved shopper experiences, and sustainable practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320389359/en/
The breakthrough of Generative Pre-trained Transformer 3 (GPT-3) technology, represented by represented by ChatGPT, has expanded the boundaries of all industries. Hanshow is Microsoft’s global strategy partner in the retail industry since 2023 and is one of the first to incorporate GenAI technology in retail scenarios using Azure OpenAI (AOAI).
At the event, Eason Tong, Dean of the Hanshow Retail Research Institute, announced Hanshow's first GenAI solution for retail business operations based on strategic cooperation with Microsoft. For retailers, Hanshow uses OpenAI's large model capabilities integrated with massive digital retail data to create the industry's first automated content (copy + image) generation intelligent application solution - the Hanshow Store Marketing Assistant.
The GenAI solution released by Hanshow relies on open source GPT-4 text output and Dall-E3 image output and can generate commodity POP posters, marketing atmosphere posters, and product copy through dialogue interaction. The internal integration of Hanshow's product ecosystem allows the generated materials to be uploaded and shown on the Hanshow Lumina Screen and upcoming large-sized colorful electronic paper posters with one click.
With the Hanshow Store Marketing Assistant, stores can easily generate a variety of creatively designed marketing materials to vividly portray product selling points while controlling marketing costs and improving sales. Whether it is a store operator or a brand owner, retailers can use the solution to reduce creative work from several hours to a few minutes.
"Hanshow is dedicated to offering retailers a retail media network solution that diversifies income streams. Leveraging generative AI for content, personalization, and impact assessment, we support future store media networks comprehensively," said Tong.
Microsoft and its ecosystem have supported Hanshow in building a digital store solution based on Azure OpenAI capabilities, and the two parties are deepening their cooperation and accelerating the landing of generative AI in global physical retail scenarios.
Microsoft and Hanshow jointly held a high-level roundtable forum to explore revolutionary omnichannel GenAI retail applications and trends and the green development and digital transformation of the retail industry.
"GenAI's remarkable capabilities are revolutionizing various industries. We're delighted to see Hanshow, Microsoft's global strategic partner, leveraging Azure OpenAI technology to introduce generative AI into physical retail. As a pioneer in retail digitalization, Hanshow combines industry insights with GenAI to present innovative digital store solutions," stated Frank Kong, Microsoft China's General Manager of Retail Consumer Goods.
Coming up, Hanshow and Microsoft’s GenAI marketing solutions for consumers will also be unveiled at the NRF exhibition in Singapore in June 2024, covering the four areas of store operations, consumer experience, store media, and green energy.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320389359/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom